Equities analysts expect that Amarin Co. (NASDAQ:AMRN) will report ($0.07) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Amarin’s earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.05). Amarin posted earnings of ($0.08) per share during the same quarter last year, which would indicate a positive year over year growth rate of 12.5%. The firm is expected to issue its next earnings report on Wednesday, May 2nd.
According to Zacks, analysts expect that Amarin will report full-year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.44) to ($0.19). For the next year, analysts anticipate that the business will post earnings of $0.09 per share, with EPS estimates ranging from ($0.11) to $0.25. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Amarin.
Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). The business had revenue of $53.87 million during the quarter, compared to the consensus estimate of $52.73 million. The business’s revenue was up 39.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.10) earnings per share.
NASDAQ AMRN traded down $0.05 on Thursday, reaching $2.94. 3,679,278 shares of the company were exchanged, compared to its average volume of 1,924,240. The firm has a market capitalization of $859.41, a P/E ratio of -11.76 and a beta of 0.72. The company has a debt-to-equity ratio of -1.12, a quick ratio of 1.13 and a current ratio of 1.41. Amarin has a fifty-two week low of $2.82 and a fifty-two week high of $4.60.
In other news, General Counsel Joseph T. Kennedy sold 44,857 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $3.73, for a total value of $167,316.61. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Steven B. Ketchum sold 135,205 shares of the company’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $4.41, for a total value of $596,254.05. The disclosure for this sale can be found here. In the last ninety days, insiders sold 207,004 shares of company stock worth $841,702. Corporate insiders own 3.72% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. OppenheimerFunds Inc. lifted its stake in shares of Amarin by 20.9% in the 4th quarter. OppenheimerFunds Inc. now owns 7,897,310 shares of the biopharmaceutical company’s stock valued at $31,668,000 after purchasing an additional 1,365,720 shares during the last quarter. Hoylecohen LLC purchased a new stake in shares of Amarin in the 4th quarter valued at $142,000. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Amarin by 70.9% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 245,510 shares of the biopharmaceutical company’s stock valued at $984,000 after buying an additional 101,860 shares during the period. Two Sigma Investments LP raised its holdings in shares of Amarin by 41.1% in the 4th quarter. Two Sigma Investments LP now owns 1,547,977 shares of the biopharmaceutical company’s stock valued at $6,207,000 after buying an additional 450,755 shares during the period. Finally, Alps Advisors Inc. purchased a new stake in shares of Amarin in the 4th quarter valued at $1,203,000. 38.16% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Brokerages Expect Amarin Co. (AMRN) to Post -$0.07 Earnings Per Share” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://stocknewstimes.com/2018/04/22/brokerages-expect-amarin-co-amrn-to-post-0-07-earnings-per-share.html.
Amarin Company Profile
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.